| Autor: |
Halpern, James, Akbar, Faraz, Cuell, Alexis, Sarapuddin, Ben |
| Předmět: |
|
| Zdroj: |
Dermatological Nursing; Sep2023, Vol. 22 Issue 3, p35-38, 4p |
| Abstrakt: |
Tralokinumab is an anti-interleukin-13 monoclonal antibody approved in several geographical regions for the treatment of moderate-to-severe atopic dermatitis. This manuscript presents three case studies of patients with moderate-to-severe atopic dermatitis who had failed on prior treatments and took part in trials of tralokinumab. Data is available for approximately two years in each patient and indicates that treatment with tralokinumab every two weeks was associated with substantial improvements in patient itch, sleep and quality of life, with feedback from the patients suggesting that this had a meaningful impact on their daily lives. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
